178 related articles for article (PubMed ID: 20852150)
21. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
22. Epidermal expression of transforming growth factor-alpha in transgenic mice: induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression.
Wang XJ; Greenhalgh DA; Eckhardt JN; Rothnagel JA; Roop DR
Mol Carcinog; 1994 May; 10(1):15-22. PubMed ID: 8185825
[TBL] [Abstract][Full Text] [Related]
23. TGF-β1 as possible link between loss of bone mineral density and chronic inflammation.
Ehnert S; Baur J; Schmitt A; Neumaier M; Lucke M; Dooley S; Vester H; Wildemann B; Stöckle U; Nussler AK
PLoS One; 2010 Nov; 5(11):e14073. PubMed ID: 21124921
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
[TBL] [Abstract][Full Text] [Related]
25. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Halder SK; Beauchamp RD; Datta PK
Neoplasia; 2005 May; 7(5):509-21. PubMed ID: 15967103
[TBL] [Abstract][Full Text] [Related]
26. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor.
Burch ML; Ballinger ML; Yang SNY; Getachew R; Itman C; Loveland K; Osman N; Little PJ
J Biol Chem; 2010 Aug; 285(35):26798-26805. PubMed ID: 20571025
[TBL] [Abstract][Full Text] [Related]
27. Diabetes-relevant regulation of cultured blood outgrowth endothelial cells.
Wang S; Hirschberg R
Microvasc Res; 2009 Sep; 78(2):174-9. PubMed ID: 19539633
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.
Chan KS; Carbajal S; Kiguchi K; Clifford J; Sano S; DiGiovanni J
Cancer Res; 2004 Apr; 64(7):2382-9. PubMed ID: 15059889
[TBL] [Abstract][Full Text] [Related]
29. Activation of the ALK-5 Pathway is not per se Sufficient for the Antiproliferative Effect of TGF-β1 on Renal Tubule Epithelial Cells.
García-Sánchez O; Sancho-Martínez SM; López-Novoa JM; López-Hernández FJ
Cell Physiol Biochem; 2015; 37(4):1231-9. PubMed ID: 26431052
[TBL] [Abstract][Full Text] [Related]
30. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
31. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin.
Owens DM; Spalding JW; Tennant RW; Smart RC
Cancer Res; 1995 Jul; 55(14):3171-8. PubMed ID: 7606738
[TBL] [Abstract][Full Text] [Related]
32. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.
You HJ; Bruinsma MW; How T; Ostrander JH; Blobe GC
Carcinogenesis; 2007 Dec; 28(12):2491-500. PubMed ID: 17768179
[TBL] [Abstract][Full Text] [Related]
33. Stromal regulation of vessel stability by MMP14 and TGFbeta.
Sounni NE; Dehne K; van Kempen L; Egeblad M; Affara NI; Cuevas I; Wiesen J; Junankar S; Korets L; Lee J; Shen J; Morrison CJ; Overall CM; Krane SM; Werb Z; Boudreau N; Coussens LM
Dis Model Mech; 2010; 3(5-6):317-32. PubMed ID: 20223936
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad- and p38-dependent mechanisms.
Walsh MF; Ampasala DR; Hatfield J; Vander Heide R; Suer S; Rishi AK; Basson MD
Am J Pathol; 2008 Aug; 173(2):385-99. PubMed ID: 18583311
[TBL] [Abstract][Full Text] [Related]
35. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
36. ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
Rodgers JJ; McClure R; Epis MR; Cohen RJ; Leedman PJ; Harvey JM; ; Thomas MA; Bentel JM
J Cell Biochem; 2019 Jan; 120(1):848-860. PubMed ID: 30161276
[TBL] [Abstract][Full Text] [Related]
37. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression.
Liu Z; Kobayashi K; van Dinther M; van Heiningen SH; Valdimarsdottir G; van Laar T; Scharpfenecker M; Löwik CW; Goumans MJ; Ten Dijke P; Pardali E
J Cell Sci; 2009 Sep; 122(Pt 18):3294-302. PubMed ID: 19706683
[TBL] [Abstract][Full Text] [Related]
38. The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development.
Chun KS; Lao HC; Trempus CS; Okada M; Langenbach R
Carcinogenesis; 2009 Sep; 30(9):1620-7. PubMed ID: 19587094
[TBL] [Abstract][Full Text] [Related]
39. ALK5 inhibition blocks TGFß-induced CCN2 expression in gingival fibroblasts.
Thompson K; Hamilton DW; Leask A
J Dent Res; 2010 Dec; 89(12):1450-4. PubMed ID: 20924066
[TBL] [Abstract][Full Text] [Related]
40. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
Koo BH; Kim Y; Je Cho Y; Kim DS
Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
